Universidad Austral de Chile-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2019

  1. Tanycytes: A rich morphological history to underpin future molecular and physiological investigations

    Journal of Neuroendocrinology, Vol. 31, Núm. 3

2017

  1. Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow

    Fluids and Barriers of the CNS, Vol. 14, Núm. 1

  2. Regulation of membrane ruffling by polarized STIM1 and ORAI1 in cortactin-rich domains

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. A pharmacist's role in the individualization of treatment of HIV patients

    Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  5. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

2014

  1. Dose reduction of efavirenz: An observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics

    Pharmacogenomics, Vol. 15, Núm. 7, pp. 997-1006

  2. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

  2. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2011

  1. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  3. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

2010

  1. Cell organization of the rat pars tuberalis. Evidence for open communication between pars tuberalis cells, cerebrospinal fluid and tanycytes

    Cell and Tissue Research, Vol. 339, Núm. 2, pp. 359-381

  2. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

  3. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: The former opens to the portal blood and the latter to the cerebrospinal fluid

    Peptides, Vol. 31, Núm. 4, pp. 757-776

2009

  1. Hyperhidrosis in association with efavirenz

    AIDS Patient Care and STDs, Vol. 23, Núm. 3, pp. 143-145